Roche’s Tecentriq plus chemo meets PFS goal in triple negative breast cancer

This article was originally published here

Roche said that a phase 3 study evaluating the Tecentriq (atezolizumab) and chemotherapy combination as a first-line treatment for triple negative breast cancer met its co-primary endpoint of progression-free survival (PFS).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply